Immuno-oncology company Neon Therapeutics has been launched with $55m of series A capital supplied by investors including Access Industries.
Venture capital firm Third Rock Ventures launched a US-based immuno-oncology company called Neon Therapeutics yesterday with $55m of funding provided by investors including conglomerate Access Industries.
Access and Third Rock were joined in the series A round by healthcare-focused investment holding company Clal Biotechnology Industries.
Neon will look to develop cancer treatments that target proteins called neoantigens in order to help the immune system attack tumours. Neoantigens spring from mutations caused by cancer growth, and Neon hopes that helping the…
